Follow Us:Respiratio 2023, 13, (1-2):45-56
METABOLIC SYNDROME (METS) AS ONE OF THE MAJOR COMORBIDITIES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Daniela Buklioska Ilievska1,2, Marjan Baloski23, Jane Bushev2,3, Jordan Minov1,2, Ivana Mickovski2,1, Irena Gigovska Dimova2,3, Natasha Eftimovska Otovikj1,2, Radmila Milosheska2
Original Research
Naučni članak
Aim: We aimed to investigate the association between COPD and MetS, the relation to the severity of airflow limitation.
Methods: This is a cross-sectional study including 220 patients with initially diagnosed COPD (IG), aged 40 to 75 years and 58 non-COPD subjects matched by age, smoking status, body mass index, as controls (CG). All study participants underwent anthropometric measurements, fasting blood sugar (FBS), lipid profile, pulmonary evaluation (dyspnea severity assessment, baseline and postbronchodilator spirometry, gas analyses, chest X-ray).
Results: Results presented statistically significant difference in presence of MetS in COPD patients compared to controls (32.27% vs 10.34%; P=0.0009). According to the GOLD classification, the frequencies of MetS in COPD patients were categorized in stages I, II, III, IV (17.54%, 37.10%, 34.62%, 40.82%, respectively). The proportion of patients with increased glycemic values was: a) GOLD1 - 18 (31.58%); b) GOLD 2 - 32 (51.61%); c) GOLD3 - 29 (55.77%); and d) GOLD4 - 31 (63.27%). There was no significant difference between IG and CG patients regarding HDL level. According to arterial hypertension the highest proportion was observed in GOLD3 - 22 (42.31%) followed by GOLD4 - 20 (40.82%), and GOLD3 - 22 (35.48 %), smallest in GOLD1 - 17 (29.82%).
Conclusion: We found higher prevalence of MetS in patients with COPD even in early COPD stages compared to non-COPD. Our findings suggest an urgent need to develop comprehensive strategies for prevention, screening and start of treatment in early stage.
Key words: COPD, metabolic syndrome, dyslipidemia, obesity.
LITERATURA
|
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Executive Summary: Global Strategy for Diagnosis, Management, and Prevention of COPD - Updated 2022. Available from: https://2022 GOLD Reports - Global Initiative for Chronic Obstructive Lung Disease - GOLD (goldcopd.org) |
|
|
|
|
|
2. Varga JT. Smoking and pulmonary complications: respiratory rehabilitation. J Thorac Dis 2019; 11(5):639-644. [CrossRef] PMid:31080640 PMCid:PMC6503270 |
|
|
|
|
|
3. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med. 2011;5(5):647-662. |
|
|
|
|
|
4. Choi HS, Rhee CK, Park YB, Yoo KH, Lim SY. Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs. Int J Chron Obstruct Pulmon Dis. 2019;10(14):2873-2883. |
|
|
|
|
|
5. Naik D, Joshi A, Paul TV, Thomas N. Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat. Indian J Endocrinol Metab. 2014;18(5):608-16. [CrossRef] PMid:25285275 PMCid:PMC4171881 |
|
|
|
|
|
6. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645. [CrossRef] PMid:19805654 |
|
|
|
|
|
7. Zhou W, Li CL, Cao J, Feng J. Metabolic syndrome prevalence in patients with obstructive sleep apnea syndrome and chronic obstructive pulmonary disease: Relationship with systemic inflammation. Clin Respir J. 2020;14(12):1159-1165. [CrossRef] PMid:32777167 PMCid:PMC7756725 |
|
|
|
|
|
8. Acharyya A, Shahjahan MD, Mesbah FB, et al. Association of metabolic syndrome with chronic obstructive pulmonary disease in an Indian population. Lung India 2016;33:385-90. |
|
|
|
|
|
9. Mohammad G. Saklayen. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. [CrossRef] PMid:29480368 PMCid:PMC5866840 |
|
|
|
|
|
10. World Health Organization. Guidelines for controlling and monitoring the tobbaco epidemic. Geneva: WHO, 1998. |
|
|
|
|
|
11. Minette A. Questionnaire of the European Community for Coal and Steel (ECSC) on respiratory symptoms. 1987 - updating of the 1962 and 1967 questionnaires for studying chronic bronchitis and emphysema. Eur Respir J. 1989;2:165-177. |
|
|
|
|
|
12. European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Respiratory Health Survey (ECRHS). Eur Respir J. 1996; 9:687-695. |
|
|
|
|
|
13. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 1960; 2:1662. |
|
|
|
|
|
14. Miller МР, Hankinson Ј, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005; 26:319-338.[CrossRef] PMid:16055882 |
|
|
|
|
|
15. American Heart Association. Symptoms and Diagnosis of Metabolic Syndrome. Updated: Apr 13, 2017. Available at: http://www.heart.org/ (assessed 20.12.2022). |
|
|
|
|
|
16. Vizza C et al. Pulmonary Hypertension in patients With COPD. Results From the Comparative, prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). CHEST 2021;160(2);678-689. |
|
|
|
|
|
17. Baffi CW, Wood L, Winnica D, et al. Metabolic syndrome and the lung. Chest. 2016;149:1525-34. [CrossRef] PMid:26836925 PMCid:PMC4944780 |
|
|
|
|
|
18. Choi HS, Rhee CK, Park YB, et al. Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs. Int J Chron Obstruct Pulmon Dis. 2019;14:2873-2883. [CrossRef] PMid:31849460 PMCid:PMC6911318 |
|
|
|
|
|
19. Naseem S, Baneen U. Systemic inflammation in patients of chronic obstructive pulmonary disease with metabolic syndrome. J Family Med Prim Care. 2019;8:3393-3398. |
|
|
|
|
|
20. Dave L, Garde S, Ansari OA, et al. A study of association between metabolic syndrome and COPD. J Evol Med Dent Sci. 2014;3:6183-8. [CrossRef] |
|
|
|
|
|
21. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, Sørensen TI, Lange P. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006;173(1):79-83. [CrossRef] PMid:16368793 |
|
|
|
|
|
22. Sun, Y., Milne, S., Jaw, J.E. et al. BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res 2019;20:236. |
|
1. Ss. Cyril and Methodius University in Skopje, Medical Faculty
2. City General Hospital ,,8mi Septemvri“ – Skopje, Macedonia
3. Goce Delchev University in Shtip, Macedonia